Top Markets
#1 GoPlus Security GoPlus Security +40.91%
#2 Tutorial Tutorial +21.27%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.85%
#4 Pons Pons +18.51%
#5 Status Status +14.44%
#6 SkyAI SkyAI +13.40%
#7 Verus Coin Verus Coin +13.11%
#8 Nillion Nillion +8.72%
#9 BankrCoin BankrCoin +8.66%
#10 Talus Network Talus Network +8.55%
Coin of the day
GoPlus Security GoPlus Security
Settings
Language
ENGLISH
Currency
USD
Theme
Polydex Pharmaceuticals Limited Polydex Pharmaceuticals Limited

Polydex Pharmaceuticals Limited

POLXF
Rank in Stocks #33818
Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was... Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.
Share Price
$1.99
Last synced: 2023-08-07
Market Cap
$6.82M
Change (1 day)
0.30%
Change (1 year)
0.00%
Country
CA
Trade Polydex Pharmaceuticals Limited (POLXF)

Category

Healthcare
P/E ratio for Polydex Pharmaceuticals Limited (POLXF)
P/E ratio as of 2026 TTM: 0
According to Polydex Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Polydex Pharmaceuticals Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.